Management of Otitis

Total Page:16

File Type:pdf, Size:1020Kb

Management of Otitis Chronic and recurrent otitis is Management of Otitis frustrating! • Otitis externa is the most common ear disease in the cat and dog • Reported incidence is 10-20% in the dog Lindsay McKay, DVM, DACVD and 2-10% in the cat [email protected] • It is a common reason for referral to VCA Arboretum View Animal Hospital dermatology specialists and very common clinical problem for general practitioners 1- Primary causes- directly Breaking down the problem induce otic inflammation • ALLERGIES (atopy and food allergies) • Step 1- Identify the primary cause of otitis • Parasites (Otodectes cyanotis, Demodicosis) • Step 2- Assess for predisposing factors of • Masses (tumors and polyps) otitis • Foreign bodies (ex plant awns, hair, • Step 3- Treat the secondary infections ceruminoliths, hardened medications) • Step 4- Identify the perpetuating factors of • Disorders of keratinization (hypothyroidism, otitis primary seborrhea, sebaceous adenitis) • Immune mediated disease (pemphigus, juvenile cellulitis, vasculitis) What are most common causes of 2- Predisposing factors of ear disease recurrent otitis…. • These factors facilitate inflammation by changing • Allergic disease in the dog- over 40% cases environment of the ear! in one study • Ear conformation- stenotic • Polyps and ear mites in the cat canals, hair in canals, pendulous ears • Excessive moisture or cerumen production • Treatment effects- irritation from meds/contact allergy or trauma from cleaning 1 3- Secondary bacterial and/or 4- Perpetuating factors- prevent yeast infections the resolution of otitis • Epithelial thickening, • Address with ear glandular hypertrophy cleaning, topical • Dermal fibrosis, antimicrobial agents, cartilage mineralization most often topical steroids and in some • Stenosis of lumen cases systemic anti- • OTITIS MEDIA infectives and systemic steroids Otitis Externa Otitis Media Clinical Signs Physical Exam Findings • Head shaking • +/- Pinnal erythema and hair loss • Scratching/rubbing at ears • Erythema, swelling and • Otitis media- inflammation of the middle ear • Odor debris present in the external • Pain ear canal • Often an extension of otitis externa through a • Itchiness in other • +/- Ceruminous gland ruptured tympanic membrane locations hyperplasia • Ear drum appears normal and • May also occur from polyps or neoplasia intact within the middle ear • +/- Concurrent skin disease Clinical signs of Otitis media Otitis media • In dogs with recurrent ear infections for 6 Clinical Signs Physical Exam Findings months or longer, up to 82% had • Elevated third eyelid • Ruptured or intact tympanic 1 concurrent otitis media • Drooping lip on one side membrane • Intact membrane can be • AND in 71% of these cases of otitis media, • Parasympathetic nose- 1 bulging, hemorrhagic, the ear drum was intact at time of diagnosis unilateral hyperkeratosis discolored and exudate may • Treatment of otitis media often involves • Pain, odor, head shaking be visible greater than 6 weeks of systemic antibiotics (any and all signs of otitis • Neurologic abnormalities- externa) Horner’s syndrome, facial • Deep ear flush under general anesthesia • Balance issues, head tilt (if nerve paralysis greatly aids therapy of otitis media concurrent otitis interna) • Neuro signs of otitis interna- peripheral vestibular 1. Saridomichelakis MN et al. Aetiology of canine otitis externa: a retrospective study • Hearing loss disease, and deafness of 100 cases. Vet Derm 2007; 18: 341-347 2 Otoscopy Otoscopy • Evaluate both ears Normal – Use separate cone for each ear – Ear pinnae – Vertical ear canal • Horizontal and vertical canals – Horizontal ear canal – Sebaceous glands- associated with HF, density greatest proximally – “Noxon’s Ridge” – Ceruminous glands- greatest density deep in ear canal – Tympanic membrane – Hair follicles- decrease in number distal to proximal (outside to inside) – There are a few fine hairs at entrance of external Noxon’s Ridge acoustic meatus, serve as helpful landmark for locating the eardrum A normal ear is self cleaning! Otoscopy Normal • Epithelial migration- epithelium in the ear canal grows outward from the tympanic membrane toward opening of the external • Horizontal and vertical canals ear canal – Light pink – Smooth • Epithelial cells carry debris with them – Minimal exudates • When this is disrupted, we can see ceruminoliths – Vertical canal 5-10 mm diameter where it meets • Ear canal masses also interrupt self cleaning horizontal canal Otoscopy Otoscopy Abnormal Normal • Glandular hyperplasia – Acute: • Tympanic membrane • Enlargement and – Pars flaccida hypersecretion • Upper quadrant – Chronic: • Elongated, full of colloidal • Pink with small vessels cellular debris • Little secretory activity, duct openings plugged • Loosely attached 3 Otoscopy Normal Canine Otoscopy Normal Feline • Tympanic membrane • Manubrium of malleus – Pars tensa is straighter in cats • Pearl-gray • Thin • Radiating bands • Tough – Manubrium of malleus (stria mallearis is outline of manubrium of malleus that can be visualized Curve points towards through membrane) the nose! Otoscopy Otoscopy Abnormal Abnormal • Ceruminolith • Mass behind tympanic • Mass membrane • Foreign Body • Abnormal tympanic membrane • Inflammation • Ruptured tympanic • Excess exudates membrane Tympanic Cavity Tympanic Cavity DOG CAT DOG CAT • Divided into 2 cavities by an • Consists of small almost complete bony septum epitympanic recess and • Larger cavity is the large ventral bulla ventromedial compartment • There is incomplete bony • To gain access you would need septum (Rosychuk’s Ridge) to break down this bony that allows communication septum = likely nerve between dorsal and ventral damage!! cavities • Leave that to surgeons! Refer for VBO if imaging shows mass or exudate there! 4 Therapy of otitis externa Therapy of otitis media 1- Keep ear canal clean 1- Keep ear canal clean 2- Topical and/or systemic anti-inflammatory therapy 2- Topical anti-inflammatory therapy 3- Topical antibiotics/ antimicrobials 3- Topical antibiotics/ antimicrobials 4- Systemic antibiotics and/or antifungals 4- TREAT THE UNDERLYING CAUSE 5- Deep ear flush and otoscopy under general 5- Monitor response to therapy with recheck anesthesia exams and otic cytology 6- TREAT THE UNDERLYING CAUSE 7- Monitor response to therapy with recheck exams and otic cytology 1- Keep the ear clean 1- Keep the ear clean • Ear cleanser options: • Removes the nidus (ex. cerumen) of infection o Epiotic Advanced- creates acidified ear • Removes bacterial and inflammatory debris canal • Allows antimicrobials to penetrate the entire o Douxo Micellar or ear canal Cerumene- • Prevents purulent debris from inactivating ceruminolytics antimicrobial agents, especially important for • Clean every 1-2 days aminoglycosides Ear cleaning instructions for Following cleaning, presoak with owners- the gauze method Triz EDTA • 3 by 3 gauze • Indicated in bacterial • Wet gauze with cleaner or infections, especially when pour cleaner into canal rod shaped bacteria such as • Gently massage gauze into Pseudomonas present ear canals • Presoak the canal with Tris- • It wicks up debris and EDTA product prior to cleans ear gently medicating • Repeat until clean gauze • Do not wipe clean emerges • Tends to be very well • Done on a daily basis, prior tolerated! to medicating ear 5 2- Topical and Systemic Steroids 3- Topical therapy yeast otitis • Unless medically contra-indicated, always • Topical antifungals- miconazole, treat otitis externa with topical steroids clotrimazole, ketoconazole • In preparation for deep ear flush and/or • Can be used alone, or in conjunction with painful swollen ears- add 2-3 week course steroids of oral glucocorticoids • Treat over 3-4 weeks with topical therapy • Steroids decrease inflammation and • In otitis externa/ media, treat until external production of cerumen, reduce swelling and canal cytology is negative stenosis of canal, and make pets less painful 3- Topical therapy- Antifungal topical recipes bacterial otitis • Miconazole 2% (1.5 to 3ml) with Synotic • First time infections- cocci- gentamicin, (8ml bottle) florfenicol, Polymixin B or orbifloxacin are • Miconazole 2% (20 ml) with good choices Dexamethasone 2 mg/ml (5-10ml) • First time infections- cocci, rods- gentamicin, • Clotrimazole can be substituted enrofloxacin, orbifloxacin and Polymixin B • Treat for 3-4 week period • Important to recheck prior to end of therapy to ensure that infection has resolved The role of Pseudomonas in canine otitis Clinical Signs- Pseudomonas otitis • Pseudomonas aeruginosa- aerobic, gram • Head shaking or negative rod bacteria scratching • Associated with chronic otitis externa and • Purulent exudate media in the dog • Malodor • Swelling, • Isolated in up to 20% of dogs with otitis inflammation and pain • Rapidly develops multi-drug resistance • Ulceration • OTITIS MEDIA 6 Recognize biofilm when you see it Therapy of Pseudomonas otitis • Ear cytology from ear chronically infected with 1- Keep ear canal clean Pseudomonas aeruginosa 2- Topical antibiotics/ antimicrobials toxic neutrophils, numerous rod bacteria, some within colonies 3- Systemic antibiotics in the dark purple material 4- Deep ear flush and otoscopy under general which is biofilm anesthesia • Culture and sensitivity is indicated for most cases where 5- Topical and/or systemic anti-inflammatory rods are seen and especially if therapy biofilm noted • Start preparing owner for deep 6- TREAT THE UNDERLYING CAUSE ear cleaning Pseudomonas ear infection Antibiotics with potential
Recommended publications
  • Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications
    International Journal of Molecular Sciences Review Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications Daniel Fernández-Villa 1, Maria Rosa Aguilar 1,2 and Luis Rojo 1,2,* 1 Instituto de Ciencia y Tecnología de Polímeros, Consejo Superior de Investigaciones Científicas, CSIC, 28006 Madrid, Spain; [email protected] (D.F.-V.); [email protected] (M.R.A.) 2 Consorcio Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, 28029 Madrid, Spain * Correspondence: [email protected]; Tel.: +34-915-622-900 Received: 18 September 2019; Accepted: 7 October 2019; Published: 9 October 2019 Abstract: Bacterial, protozoan and other microbial infections share an accelerated metabolic rate. In order to ensure a proper functioning of cell replication and proteins and nucleic acids synthesis processes, folate metabolism rate is also increased in these cases. For this reason, folic acid antagonists have been used since their discovery to treat different kinds of microbial infections, taking advantage of this metabolic difference when compared with human cells. However, resistances to these compounds have emerged since then and only combined therapies are currently used in clinic. In addition, some of these compounds have been found to have an immunomodulatory behavior that allows clinicians using them as anti-inflammatory or immunosuppressive drugs. Therefore, the aim of this review is to provide an updated state-of-the-art on the use of antifolates as antibacterial and immunomodulating agents in the clinical setting, as well as to present their action mechanisms and currently investigated biomedical applications. Keywords: folic acid antagonists; antifolates; antibiotics; antibacterials; immunomodulation; sulfonamides; antimalarial 1.
    [Show full text]
  • Application of HPLC Method in Determination of Miconazole Nitrate in Environmental Samples from El-Gharbia Governorate in Egypt
    Journal of Analytical & Pharmaceutical Research Research Article Open Access Application of HPLC method in determination of miconazole nitrate in environmental samples from el-gharbia governorate in Egypt Abstract Volume 8 Issue 4 - 2019 This paper describes an enhanced High-performance liquid chromatography (HPLC) method for the analysis of miconazole in water samples. In this study, determination of Mohamed W Ibrahim,1 Ahmad A Mohamad,2 miconazole has been carried out according to standard method for water and wastewater Ahmed M Ahmed3 analysis. Samples of collected water were agriculture stream water, River Nile (Surface 1Department of Pharmaceutical Analytical Chemistry, Al-Azhar water samples) water and Hospital wastewater samples from El-gharbia governorate in University, Egypt Egypt. Miconazole was extracted by liquid-liquid extraction and analyzed by HPLC. The 2Department of Pharmaceutical Analytical Chemistry chromatographic separation was performed using a Phenomenex C8 column, flow rate of Department, Heliopolis University, Egypt 0.8mL/min, and UV detection at 220nm. The optimized HPLC system was achieved using 3Pharmacist Research Laboratories, Egypt mobile phase composition containing methanol: water (85:15v/v). The intra-day and inter- day precisions were lower than 0.58 while the accuracy ranged from 99.06% to 101.53%. Correspondence: Ahmed M Ahmed, Pharmacist Research Finally, liquid-liquid phase extraction in combination with HPLC is a sensitive and effective Laboratories, Ministry of health, Giza, Egypt, Tel +201119538119, method for the determination of Miconazole Nitrate in water samples. Miconazole was Email [email protected] observed in some agricultural streams and waste water samples of El-gharbia governorate Received: August 06, 2019 | Published: August 14, 2019 hospitals.
    [Show full text]
  • 4. Antibacterial/Steroid Combination Therapy in Infected Eczema
    Acta Derm Venereol 2008; Suppl 216: 28–34 4. Antibacterial/steroid combination therapy in infected eczema Anthony C. CHU Infection with Staphylococcus aureus is common in all present, the use of anti-staphylococcal agents with top- forms of eczema. Production of superantigens by S. aureus ical corticosteroids has been shown to produce greater increases skin inflammation in eczema; antibacterial clinical improvement than topical corticosteroids alone treatment is thus pivotal. Poor patient compliance is a (6, 7). These findings are in keeping with the demon- major cause of treatment failure; combination prepara- stration that S. aureus can be isolated from more than tions that contain an antibacterial and a topical steroid 90% of atopic eczema skin lesions (8); in one study, it and that work quickly can improve compliance and thus was isolated from 100% of lesional skin and 79% of treatment outcome. Fusidic acid has advantages over normal skin in patients with atopic eczema (9). other available topical antibacterial agents – neomycin, We observed similar rates of infection in a prospective gentamicin, clioquinol, chlortetracycline, and the anti- audit at the Hammersmith Hospital, in which all new fungal agent miconazole. The clinical efficacy, antibac- patients referred with atopic eczema were evaluated. In terial activity and cosmetic acceptability of fusidic acid/ a 2-month period, 30 patients were referred (22 children corticosteroid combinations are similar to or better than and 8 adults). The reason given by the primary health those of comparator combinations. Fusidic acid/steroid physician for referral in 29 was failure to respond to combinations work quickly with observable improvement prescribed treatment, and one patient was referred be- within the first week.
    [Show full text]
  • FLAMAZINE™ CREAM 1.0% W/W
    PRODUCT INFORMATION NAME OF THE MEDICINE: FLAMAZINE™ CREAM 1.0% w/w Silver sulfadiazine 1% w/w Composition: Active ingredient. Silver sulfadiazine. Excipients. Polysorbate 60 Ph. Eur, Polysorbate 80 Ph. Eur, Glyceryl Monostearate Ph. Eur, Cetyl Alcohol Ph. Eur, Liquid Paraffin Ph. Eur, Propylene Glycol Ph. Eur and Purified Water Ph. Eur. DESCRIPTION: A sterile white hydrophilic cream containing silver sulfadiazine 1%. The cream is a semisolid oil-in-water emulsion. The silver sulfadiazine is in a fine micronised form. Silver sulfadiazine is a white or creamy-white, odourless or almost odourless crystalline powder, which becomes yellow on exposure to light. Practically insoluble in water; slightly soluble in acetone; practically insoluble in alcohol, chloroform or ether; freely soluble in strong ammonia solution. Chemical name: Silver salt of N’-(pyrimidin-2-yl)sulfanilamide. C10H9AgN4O2S. M.W. 357.1 CAS 22199-08-2 Chemical structure: PHARMACOLOGY: Silver sulfadiazine is a sulfonamide and has broad antimicrobial activity against both Gram- positive and Gram-negative organisms. Silver sulfadiazine acts on the cell membrane and cell wall. Unlike sulfadiazine or other sulfonamides, the antibacterial action of the silver salt of sulfadiazine does not appear to depend on inhibition of folic acid synthesis. Its action is not antagonised by p-aminobenzoic acid. Flamazine Cream: 1 June 2010 1 of 6 Microbiology: Silver sulfadiazine has broad antimicrobial activity against both Gram-positive and Gram-negative organisms including Pseudomonas aeruginosa, some yeasts and fungi. It has also been reported to be active in vitro against herpes virus and Treponema pallidum. Sulfonamides act by interfering with the synthesis of nucleic acids in sensitive micro- organisms by blocking the conversion of p- aminobenzoic acid to the co-enzyme dihydrofolic acid.
    [Show full text]
  • ANNOVERA™ (Segesterone Acetate and Ethinyl Estradiol Vaginal System) • Risk of Liver Enzyme Elevations with Concomitant Hepatitis C Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION ANNOVERA™ no earlier than 4 weeks after delivery, in females who These highlights do not include all the information needed to use are not breastfeeding. Consider cardiovascular risk factors before ANNOVERA™ safely and effectively. initiating in all females, particularly those over 35 years. (5.1, 5.5) See Full Prescribing Information for ANNOVERA™. • Liver Disease: Discontinue if jaundice occurs. (5.2) ANNOVERA™ (segesterone acetate and ethinyl estradiol vaginal system) • Risk of Liver Enzyme Elevations with Concomitant Hepatitis C Initial U.S. Approval: 2018 Treatment: Stop ANNOVERA™ prior to starting therapy with the combination drug regimen ombitasvir/paritaprevir/ritonavir. ANNOVERA™ can be restarted 2 weeks following completion of this WARNING: CIGARETTE SMOKING AND regimen. (5.3) SERIOUS CARDIOVASCULAR EVENTS • Hypertension: Do not prescribe ANNOVERA™ for females with See full prescribing information for complete boxed warning. uncontrolled hypertension or hypertension with vascular disease. If • Females over 35 years old who smoke should not use used in females with well-controlled hypertension, monitor blood ANNOVERA™. (4) pressure and stop use if blood pressure rises significantly. (5.4) • Cigarette smoking increases the risk of serious cardiovascular • Carbohydrate and lipid metabolic effects: Monitor glucose in pre­ events from combination hormonal contraceptive (CHC) use. (4) diabetic and diabetic females taking ANNOVERA™. Consider an alternate contraceptive method for females with uncontrolled ----------------------------INDICATIONS AND USAGE-------------------------- dyslipidemias. (5.7) ANNOVERA™ is a progestin/estrogen CHC indicated for use by females of • Headache: Evaluate significant change in headaches and discontinue reproductive potential to prevent pregnancy. (1) ANNOVERA™ if indicated. (5.8) Limitation of use: Not adequately evaluated in females with a body mass index • Bleeding Irregularities and Amenorrhea: May cause irregular bleeding of >29 kg/m2.
    [Show full text]
  • Product Monograph Entocort®
    PRODUCT MONOGRAPH ENTOCORT® (budesonide) Controlled Ileal Release Capsules 3 mg Glucocorticosteroid for the Treatment of Crohn’s Disease Affecting the Ileum and/or Ascending Colon Tillotts Pharma GmbH Date of Preparation: Warmbacher Strasse 80 July 7, 2016 79618 Rheinfelden Date of Revision: Germany April 9, 2018 Importer/Distributor: C.R.I. 4 Innovation Drive Dundas, ON Canada, L9H 7P3 Control Number: 213259 PRODUCT MONOGRAPH NAME OF DRUG ENTOCORT® (budesonide) Controlled Ileal Release Capsules 3 mg THERAPEUTIC CLASSIFICATION Glucocorticosteroid for the Treatment of Crohn’s Disease Affecting the Ileum and/or Ascending Colon ACTIONS AND CLINICAL PHARMACOLOGY The active ingredient of ENTOCORT capsules, budesonide, is a potent non-halogenated synthetic glucocorticosteroid with high topical potency and weak systemic effects. The exact mechanism of action of glucocorticosteroids in the treatment of Crohn’s disease is not fully understood. Anti-inflammatory actions, such as the inhibition of inflammatory mediator release and inhibition of immunological cellular responses, are probably important. Data from clinical pharmacology studies and controlled clinical trials indicate that ENTOCORT capsules, at least partly, act topically. Budesonide undergoes an extensive degree (approximately 90%) of biotransformation in the liver to metabolites with low glucocorticosteroid activity. The glucocorticosteroid activity of the major metabolites, 6β- hydroxybudesonide and 16α-hydroxyprednisolone, is less than 1% of that of budesonide. The metabolism of budesonide is primarily mediated by CYP 3A4, an isozyme of cytochrome P450. The favourable separation between topical anti-inflammatory and systemic effect is due to strong glucocorticosteroid receptor affinity and an effective first pass metabolism by the liver with a short half-life. A glucocorticosteroid with such a profile is of particular importance for the local treatment of inflammatory bowel diseases such as Crohn’s disease.
    [Show full text]
  • Otitis Media and Interna
    Otitis Media and Interna (Inflammation of the Middle Ear and Inner Ear) Basics OVERVIEW • Inflammation of the middle ear (known as “otitis media”) and inner ear (known as “otitis interna”), most commonly caused by bacterial infection SIGNALMENT/DESCRIPTION OF PET Species • Dogs • Cats Breed Predilections • Cocker spaniels and other long-eared breeds • Poodles with long-term (chronic) inflammation of the ears (known as “otitis”) or the throat (known as “pharyngitis”) associated with dental disease • Primary secretory otitis media (PSOM) is described in Cavalier King Charles spaniels SIGNS/OBSERVED CHANGES IN THE PET • Depend on severity and extent of the infection; range from no signs, to those related to middle ear discomfort and nervous system involvement • Pain when opening the mouth; reluctance to chew; shaking the head; pawing at the affected ear • Head tilt • Pet may lean, veer, or roll toward the side or direction of the affected ear • Pet's sense of balance may be altered (known as “vestibular deficits”)—persistent, transient or episodic • Involvement of both ears—wide movements of the head, swinging back and forth; wobbly or incoordinated movement of the body (known as “truncal ataxia”), and possible deafness • Vomiting and nausea—may occur during the sudden (acute) phase • Facial nerve damage—the “facial nerve” goes to the muscles of the face, where it controls movement and expression, as well as to the tongue, where it is involved in the sensation of taste; signs of facial nerve damage include saliva and food dropping from the
    [Show full text]
  • Miconazole (Topical) | Memorial Sloan Kettering Cancer Center
    PATIENT & CAREGIVER EDUCATION Miconazole (Topical) This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US Aloe Vesta Antifungal [OTC]; Aloe Vesta Clear Antifungal [OTC]; Antifungal [OTC]; Azolen Tincture [OTC]; Baza Antifungal [OTC] [DSC]; Carrington Antifungal [OTC] [DSC]; Cavilon [OTC]; Critic-Aid Clear AF [OTC] [DSC]; Cruex Prescription Strength [OTC]; DermaFungal [OTC] [DSC]; Desenex Jock Itch [OTC]; Desenex [OTC]; Fungoid Tincture [OTC]; GoodSense Miconazole 1 [OTC]; Lotrimin AF Deodorant Powder [OTC]; Lotrimin AF Jock Itch Powder [OTC]; Lotrimin AF Powder [OTC]; Lotrimin AF [OTC]; Micaderm [OTC]; Micatin [OTC]; Miconazole 3; Miconazole 3 Combo-Supp [OTC]; Miconazole 7 [OTC]; Miconazole Antifungal [OTC]; Micro Guard [OTC] [DSC]; Mycozyl AP [OTC]; Podactin [OTC]; Remedy Antifungal Clear [OTC] [DSC]; Remedy Antifungal [OTC] [DSC]; Remedy Phytoplex Antifungal [OTC] [DSC]; Secura Antifungal Extra Thick [OTC] [DSC]; Secura Antifungal [OTC] [DSC]; Soothe & Cool INZO Antifungal [OTC] [DSC]; Triple Paste AF [OTC] [DSC]; Zeasorb-AF [OTC] What is this drug used for? All skin products: It is used to treat fungal infections of the skin. All vaginal products: This drug is used to treat vaginal yeast infections. Miconazole (Topical) 1/8 What do I need to tell my doctor BEFORE I take this drug? All products: If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. All skin products: If you have nail or scalp infections.
    [Show full text]
  • Nomina Histologica Veterinaria, First Edition
    NOMINA HISTOLOGICA VETERINARIA Submitted by the International Committee on Veterinary Histological Nomenclature (ICVHN) to the World Association of Veterinary Anatomists Published on the website of the World Association of Veterinary Anatomists www.wava-amav.org 2017 CONTENTS Introduction i Principles of term construction in N.H.V. iii Cytologia – Cytology 1 Textus epithelialis – Epithelial tissue 10 Textus connectivus – Connective tissue 13 Sanguis et Lympha – Blood and Lymph 17 Textus muscularis – Muscle tissue 19 Textus nervosus – Nerve tissue 20 Splanchnologia – Viscera 23 Systema digestorium – Digestive system 24 Systema respiratorium – Respiratory system 32 Systema urinarium – Urinary system 35 Organa genitalia masculina – Male genital system 38 Organa genitalia feminina – Female genital system 42 Systema endocrinum – Endocrine system 45 Systema cardiovasculare et lymphaticum [Angiologia] – Cardiovascular and lymphatic system 47 Systema nervosum – Nervous system 52 Receptores sensorii et Organa sensuum – Sensory receptors and Sense organs 58 Integumentum – Integument 64 INTRODUCTION The preparations leading to the publication of the present first edition of the Nomina Histologica Veterinaria has a long history spanning more than 50 years. Under the auspices of the World Association of Veterinary Anatomists (W.A.V.A.), the International Committee on Veterinary Anatomical Nomenclature (I.C.V.A.N.) appointed in Giessen, 1965, a Subcommittee on Histology and Embryology which started a working relation with the Subcommittee on Histology of the former International Anatomical Nomenclature Committee. In Mexico City, 1971, this Subcommittee presented a document entitled Nomina Histologica Veterinaria: A Working Draft as a basis for the continued work of the newly-appointed Subcommittee on Histological Nomenclature. This resulted in the editing of the Nomina Histologica Veterinaria: A Working Draft II (Toulouse, 1974), followed by preparations for publication of a Nomina Histologica Veterinaria.
    [Show full text]
  • Therapeutic Drug Class
    BUREAU FOR MEDICAL SERVICES EFFECTIVE WEST VIRGINIA MEDICAID PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA 07/01/2018 This is not an all-inclusive list of available covered drugs and includes only Version 2018.3e managed categories. Refer to cover page for complete list of rules governing this PDL. • Prior authorization for a non-preferred agent in any class will be given only if there has been a trial of the preferred brand/generic equivalent or preferred formulation of the active ingredient, at a therapeutic dose, that resulted in a partial response with a documented intolerance. • Prior authorization of a non-preferred isomer, pro-drug, or metabolite will be considered with a trial of a preferred parent drug of the same chemical entity, at a therapeutic dose, that resulted in a partial response with documented intolerance or a previous trial and therapy failure, at a therapeutic dose, with a preferred drug of a different chemical entity indicated to treat the submitted diagnosis. (The required trial may be overridden when documented evidence is provided that the use of these preferred agent(s) would be medically contraindicated.) • Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC drugs are not covered unless specified. • PA criteria for non-preferred agents apply in addition to general Drug Utilization Review policy that is in effect for the entire pharmacy program, including, but not limited to, appropriate dosing, duplication of therapy, etc. • The use of pharmaceutical samples will not be considered when evaluating the members’ medical condition or prior prescription history for drugs that require prior authorization.
    [Show full text]
  • Miconazole Label Statements
    Miconazole Label Statements Consultation on need for a warning regarding interaction with warfarin and harmonisation with Australian required statements Medsafe February 2017 Medsafe consultation on LSD statements for miconazole Contents About Medsafe ....................................................................................................................................... 3 Background ............................................................................................................................................. 3 Introduction ............................................................................................................................................ 4 Interaction between warfarin and topical miconazole containing medicines ....................................... 5 Case reports ........................................................................................................................................ 5 Clinical studies .................................................................................................................................... 7 Cases reported to the Centre for Adverse Reactions Monitoring ...................................................... 7 Information published by other Regulators ....................................................................................... 8 MHRA .................................................................................................................................................. 8 Health Canada ...................................................................................................................................
    [Show full text]
  • Sulfonamides and Sulfonamide Combinations*
    Sulfonamides and Sulfonamide Combinations* Overview Due to low cost and relative efficacy against many common bacterial infections, sulfonamides and sulfonamide combinations with diaminopyrimidines are some of the most common antibacterial agents utilized in veterinary medicine. The sulfonamides are derived from sulfanilamide. These chemicals are structural analogues of ρ-aminobenzoic acid (PABA). All sulfonamides are characterized by the same chemical nucleus. Functional groups are added to the amino group or substitutions made on the amino group to facilitate varying chemical, physical and pharmacologic properties and antibacterial spectra. Most sulfonamides are too alkaline for routine parenteral use. Therefore the drug is most commonly administered orally except in life threatening systemic infections. However, sulfonamide preparations can be administered orally, intramuscularly, intravenously, intraperitoneally, intrauterally and topically. Sulfonamides are effective against Gram-positive and Gram-negative bacteria. Some protozoa, such as coccidians, Toxoplasma species and plasmodia, are generally sensitive. Chlamydia, Nocardia and Actinomyces species are also sensitive. Veterinary diseases commonly treated by sulfonamides are actinobacillosis, coccidioidosis, mastitis, metritis, colibacillosis, pododermatitis, polyarthritis, respiratory infections and toxo- plasmosis. Strains of rickettsiae, Pseudomonas, Klebsiella, Proteus, Clostridium and Leptospira species are often highly resistant. Sulfonamides are bacteriostatic antimicrobials
    [Show full text]